Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2013
10/15/2013US8557825 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
10/15/2013US8557809 Triazolopyridine compounds as PIM kinase inhibitors
10/15/2013US8557785 In vivo production of small interfering RNAS that mediate gene silencing
10/15/2013US8557780 Monomethylvaline compounds capable of conjugation to ligands
10/15/2013US8557579 Screening for modulators of PSGL-1 with respect to T cell or NK cell death
10/15/2013US8557298 Medicaments for chemotherapeutic treatment of disease
10/15/2013US8557244 Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
10/15/2013US8557240 Method for the treatment of inflammatory disorders
10/15/2013US8557238 EG-VEGF nucleic acids and polypeptides and methods of use
10/15/2013US8557233 Probiotic bifidobacterium strains
10/15/2013CA2767092C Novel compounds, pharmaceutical compositions containing same and methods of use for same
10/15/2013CA2735294C N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
10/15/2013CA2629478C Staurosporine derivatives for use in alveolar rhabdomyosarcoma
10/15/2013CA2567700C 3-triazolyl-galactoside inhibitors of galectins
10/15/2013CA2555013C Carcinoembryonic antigen fusions and uses thereof
10/15/2013CA2544562C Bispecific antibodies
10/15/2013CA2494844C Methods and compositions concerning poxviruses and cancer
10/15/2013CA2373721C Compounds that bind her2
10/10/2013WO2013152342A1 Anti-cancer mtor inhibitor and anti-androgen combination
10/10/2013WO2013152313A1 Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
10/10/2013WO2013152298A1 Compounds useful as inhibitors of atr kinase and combination therapies thereof
10/10/2013WO2013152252A1 Combination anti-cancer therapy
10/10/2013WO2013152227A1 Embelin-based delivery system for water-insoluble active agents
10/10/2013WO2013152206A1 Novel triazole compounds that modulate hsp90 activity
10/10/2013WO2013152165A1 Methods for treating cancer using pi3k inhibitor and mek inhibitor
10/10/2013WO2013152055A1 Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
10/10/2013WO2013152038A1 Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
10/10/2013WO2013152034A1 Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
10/10/2013WO2013152032A1 Compositions and methods for treating cancer
10/10/2013WO2013151999A1 Cancer treatment and immune system regulation through fat10 pathway inhibition
10/10/2013WO2013151981A1 Ewing's sarcoma bifunctional shrna design
10/10/2013WO2013151930A1 Bicyclic azaheterocyclobenzylamines as pi3k inhibitors
10/10/2013WO2013151771A1 Immunostimulatory compositions and methods of use thereof
10/10/2013WO2013151677A1 Ddr2 mutations in cancer
10/10/2013WO2013151638A1 Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
10/10/2013WO2013151161A1 Novel compound, method for producing same and antitumor agent
10/10/2013WO2013150140A1 New pyrido [3.4-c] [1.9] phenanthroline and 11, 12 dihydropyrido [3.4 -c] [1.9] phenanthroline derivatives and the use thereof, particularly for treating cancer
10/10/2013WO2013150036A1 Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
10/10/2013WO2013149997A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/10/2013WO2013149996A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/10/2013WO2013149948A1 New alkylating agents
10/10/2013WO2013149946A1 Functionalized thieno-indole derivatives for the treatment of cancer
10/10/2013WO2013149909A1 Amino-substituted imidazopyridazines
10/10/2013WO2013149800A1 Carboxamide compounds and their use as calpain inhibitors v
10/10/2013WO2013149581A1 Combination products with tyrosine kinase inhibitors and their use
10/10/2013WO2013149538A1 Pharmaceutical composition
10/10/2013WO2013149526A1 Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and t cell antigen
10/10/2013WO2013149336A1 5-nitrofuran-2-carboxamide derivatives for inhibiting centrosomal clustering
10/10/2013WO2013112186A3 Organometallic anti-cancer complexes
10/10/2013WO2013103424A9 Silk-based multifunctional biomedical platform
10/10/2013WO2013087727A8 New efficient interferon-based treating methods
10/10/2013WO2012030944A3 Quinoline and isoquinoline derivatives for use as jak modulators
10/10/2013US20130266573 Specific binding proteins and uses thereof
10/10/2013US20130266553 Albumin Fusion Proteins
10/10/2013US20130266508 Thermosensitive hydrogel for coating radioisotope and chemotherapeutic agent to treat cancer and method for preparing the same
10/10/2013CA2834083A1 Methods of treatment with arginine deiminase
10/09/2013EP2647721A1 Peptide with safer secondary structure, peptide library, and production methods for same
10/09/2013EP2647708A1 Marker for determination of sensitivity to triplet combination anti-cancer agent
10/09/2013EP2647707A1 Cytotoxicity-inducing therapeutic agent
10/09/2013EP2647638A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/09/2013EP2647637A2 Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
10/09/2013EP2647632A1 Preparation method of a-imatinib mesylate
10/09/2013EP2647629A1 Pyrazole compound having therapeutic effect on multiple myeloma
10/09/2013EP2647628A1 Substituted tricyclic compounds with activity towards ep1 receptors
10/09/2013EP2647622A1 Novel compound, and kinesin spindle protein inhibitor and application thereof
10/09/2013EP2647388A1 Antibodies Against ERBB3 and Uses Thereof
10/09/2013EP2647384A1 IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM Va-Ja , AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS
10/09/2013EP2647376A1 Nuclear receptor binding agents
10/09/2013EP2647375A1 Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
10/09/2013EP2646567A1 Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
10/09/2013EP2646546A1 Tomm34 peptides and vaccines including the same
10/09/2013EP2646472A1 Covalently dimerized bivalent binding agents
10/09/2013EP2646471A2 Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody
10/09/2013EP2646468A2 Anti-ngf compositions and use thereof
10/09/2013EP2646464A1 Anticancer fusion protein
10/09/2013EP2646456A1 Process for the preparation of morpholinyl anthracycline derivatives
10/09/2013EP2646455A2 Modulators of histone methyltransferase, and methods of use thereof
10/09/2013EP2646454A2 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
10/09/2013EP2646446A2 Bromodomain inhibitors and uses thereof
10/09/2013EP2646445A1 Oxazolo [5, 4 -b]pyridin- 5 -yl compounds and their use for the treatment of cancer
10/09/2013EP2646444A1 Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
10/09/2013EP2646441A2 Carbocycle-substituted purine and 7-deazapurine compounds
10/09/2013EP2646432A1 Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
10/09/2013EP2646430A2 Chemokine cxcr4 receptor modulators and used related thereto
10/09/2013EP2646428A1 Heterocyclic derivates preparation processes and medical uses thereof
10/09/2013EP2646427A1 Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases
10/09/2013EP2646415A1 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
10/09/2013EP2646059A2 Protease degradable polypeptides and uses thereof
10/09/2013EP2646057A2 Methods and systems for spatially identifying abnormal cells
10/09/2013EP2646047A2 Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
10/09/2013EP2646042A1 Tumour cytotoxic agent and methods thereof
10/09/2013EP2646035A2 Prodrugs of 6-cyclohexyl-1-hydroxy-4- methylpyridin-2(1h)-one and derivatives thereof
10/09/2013EP2646033A1 Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia
10/09/2013EP2646020A1 Indoles
10/09/2013EP2646007A2 Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
10/09/2013EP2646000A1 Chemoembolization composition comprising anti-angiogenic agents
10/09/2013EP2645999A2 Pharmaceutical compositions
10/09/2013EP2359854B1 Pharmaceutical compositions and methods useful for modulating angiogenesis
10/09/2013CN203227048U Dry-coated tablet as anti-tumor agent
10/09/2013CN103347897A Anti-mesothelin antibodies and immunoconjugates
1 ... 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 ... 2211